Two new GLP-1 receptor agonists for diabetes.
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D054795:Incretins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018027:Receptors, Glucagon / Q000819:agonists*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007141:Immunoglobulin Fc Fragments; D054795:Incretins; D018027:Receptors, Glucagon; D011993:Recombinant Fusion Proteins; C534611:rGLP-1 protein; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; C555680:dulaglutide